MET and Hypoalbuminemia: Dysregulation of the HGF/c-Met signaling pathway can lead to aberrant cell proliferation, drug resistance, and promotion of cell migration and invasion.15-18 In this phase Ib and expansion study, we defined a tolerable dose of ficlatuzumab when administered with gemcitabine and nab-paclitaxel, although the combination was associated with substantial rates of peripheral edema and hypoalbuminemia.